Cart
sales@molnova.com
Clivatuzumab
CAS No. 1622075-09-5
Clivatuzumab( —— )
Catalog No. M36841 CAS No. 1622075-09-5
Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 407 | In Stock |
|
| 10MG | 660 | In Stock |
|
| 25MG | 1007 | In Stock |
|
| 50MG | 1330 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameClivatuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionClivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.
-
DescriptionClivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1622075-09-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gold DV, et al. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol Cancer. 2013 Nov 20;12(1):143. ?
molnova catalog
related products
-
Nudifloric Acid
Nudifloric Acid is from Cordyceps bassiana. Nudifloric Acid targets to block AP-1-mediated luciferase activity implying it has an anti-inflammatory function.
-
Polymyxin B
Polymyxin B, an antibiotic, combats Gram-negative infections through high-affinity binding to the bacterial wall's lipopolysaccharides (LPS), neutralizing endotoxin effects and inducing bacterial cell death by enhancing permeability.
-
ELN318463 racemate
ELN 318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC50s of 12nM and 656 nM for PS1and PS2, respectively.
